Experiment challenge for hypothesis: Dual-Receptor Antibody Shuttling ## Mechanistic Hypothesis ## Mechanistic Overview Dual-Receptor Antibody Shuttling starts from the claim that modulating not yet specified within the disease context of Alzheimer's disease can redirect a disease-relevant process. The original description reads: "# Dual-Receptor Antibody Shuttling: A Strategic Approach to Overcoming Blood-Brain Barrier Limitations in Neurodegenerative Disease Therapy ## Overview The blood-brain barrier (BBB) represents the most significant obstacle to effective CNS therapeutics delivery, ## Target Gene/Pathway Not specified ## Disease Context Alzheimer's disease ## Evidence Supporting this Hypothesis [{'pmid': '41194602', 'year': '2025', 'claim': 'Ketoboronate as a Minimal Covalent-Reversible Tag for Targeted Lysosomal Degradation of Extracellular and Membrane Proteins.', 'source': 'J Am Chem Soc'}, {'pmid': '37823690', 'year': '2023', 'claim': 'Delivery of the Brainshuttle™ amyloid-beta antibod ## Evidence Against / Caveats [{'pmid': '36257298', 'year': '2022', 'claim': 'Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis.', 'source': 'paper', 'strength': ' ## Composite Score 0.803 (mechanistic plausibility: 0.70, feasibility: 0.70, impact: 0.70, confidence: 0.45)